PathAI remains an independent company, focused
on developing innovative AI and digital pathology solutions
SECAUCUS, N.J. and BOSTON, June 11,
2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a
leader in diagnostic information services, today announced that it
has completed its previously announced acquisition of PathAI
Diagnostics from PathAI, with the goal to accelerate the adoption
of AI and digital pathology to improve the diagnosis of cancer and
other diseases.
PathAI remains an independent company, dedicated to advancing AI
and digital pathology solutions for biopharmaceutical companies and
pathology laboratories. The transaction will support PathAI's
strategy to scale its investments in AI technology and expand its
software and algorithm business.
In connection with the acquisition, the PathAI Diagnostics
state-of-the-art digitized laboratory in Memphis has been rebranded as AmeriPath and
will act as the national AI and digital R&D and solutions
center supporting Quest's specialty pathology businesses, AmeriPath
and Dermpath Diagnostics. PathAI will continue to maintain a
separate research laboratory at the same site in Memphis, Tennessee to support its
biopharmaceutical clients.
In addition, PathAI and Quest have formed separate agreements to
further accelerate the adoption of AI and digital pathology based
on their strengths and scale. Specifically, Quest will license
PathAI's AISight™ digital pathology image management system to
support Quest's pathology laboratories and customer sites in
the United States. Quest is also a
preferred partner of lab services for PathAI's biopharmaceutical
clients. In addition, PathAI and Quest may also collaborate on
developing AI algorithms with potential research and clinical
applications.
Quest has a long history of strategic AI and automation
deployment. The company has implemented AI, digital and automation
technologies across several laboratory and business functions, from
microbiology and cytogenetics to specimen processing and customer
service, improving quality, efficiency and customer and employee
experiences.
About PathAI
PathAI is dedicated to improving patient
outcomes through its groundbreaking AI-powered pathology platform.
Our solutions provide invaluable insights for biopharmaceutical
companies, researchers, and pathology laboratories, ultimately
enabling precision pathology and the vision of more effective
diagnosis and treatments. Learn more at www.pathai.com.
About Quest Diagnostics
Quest Diagnostics works across
the healthcare ecosystem to create a healthier world, one life at a
time. We provide diagnostic insights from the results of our
laboratory testing to empower people, physicians and organizations
to take action to improve health outcomes. Derived from one of the
world's largest databases of deidentified clinical lab results,
Quest's diagnostic insights reveal new avenues to identify and
treat disease, inspire healthy behaviors and improve healthcare
management. Quest Diagnostics annually serves one in three adult
Americans and half the physicians and hospitals in the
United States, and our nearly
50,000 employees understand that, in the right hands and with the
right context, our diagnostic insights can inspire actions that
transform lives and create a healthier
world. www.QuestDiagnostics.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-completes-acquisition-of-select-pathai-diagnostics-lab-assets-from-pathai-accelerating-adoption-of-ai-and-digital-pathology-to-speed-cancer-diagnosis-302168364.html
SOURCE Quest Diagnostics